Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

>.  

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "goal", "should", "would", "project", "plan", "predict", "intend" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... today announced that it will be presenting at CALBIO ... 2 nd at 3pm PST. Patrick Lucy, chief business ... the current state of the biosimilar industry landscape entitled ... For more information on CALBIO 2015 and ...
(Date:2/26/2015)... , Feb. 26, 2015 S&P Capital ... Factual Stock Report coverage on MabVax Therapeutics Holdings Inc ... is a clinical stage biotechnology company focused on the ... medical needs in the treatment of cancer. MabVax has ... on the protective immune responses generated by patients who ...
(Date:2/26/2015)... Calif. , Feb. 26, 2015   Regulus ... biopharmaceutical company leading the discovery and development of innovative ... Xanthopoulos , Ph.D., President and Chief Executive Officer of ... and Company 35 th Annual Healthcare Conference on ... conference is being held at the Boston Marriott Copley ...
(Date:2/26/2015)... , Feb. 26, 2015  NuGene International, Inc. ... products for skin and hair rejuvenation, has announced ... agency of record for investor relations and strategic ... our distribution, sales and diversification strategies – and ... and prospective shareholders," stated Ali Kharazmi CEO of ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3
... - Oncolytics Biotech Inc.,(TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the ... ended December 31, 2007., "2007 was our ... of the Company,s clinical trial program for REOLYSIN(R) ... being expanded and,initiated," said Dr. Brad Thompson, President ...
... March 6 VWR Funding, Inc., the,parent company of VWR International, LLC, a leading global ... and year-end financial results., Who: ... Jack L. Wyszomierski, Executive Vice-President & Chief ... Financial Officer, When: Wednesday, March 12, ...
... on Clinical Developments, MONTREAL, March 6 /PRNewswire-FirstCall/ - ... findings from the,third cohort in its Phase II trial ... the compiled data from a,total of 18 patients showed ... at weeks 4, 6 and 8, and of the ...
Cached Biology Technology:Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 2Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 3Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 4Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 5Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 6Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 7Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 8Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 9VWR Funding, Inc. to Hold Fourth Quarter and Year-End 2007 Financial Results Conference Call 2ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia 2ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia 3
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
(Date:2/5/2015)... Calif. , Jan. 30, 2015  It is ... great power and potential for genomic science as a ... in disease prevention and treatment.  I was honored to ... new, government-funded precision medicine program. Since ... the science of genomics—from the first sequenced genome of ...
(Date:1/22/2015)... S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform its ... of Washington,s Department of Licensing, in the United ... system for driver,s licenses and identification cards to its subsidiary, ... will start in January 2015, with enrollment and card production ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Valid USA Signs Contract For Washington Driver's License Issuance 2
... Engineering (NCE) at NJIT has been selected by the National ... and colleges across the nation in a new five-year program ... selection is the culmination of a two-year long effort led ... Currently, some 43 percent of engineering undergraduates switch ...
... Loud noise, especially repeated loud noise, is known ... the cochlea and eventually lead to deafness. In mammals ... able to re-grow the damaged hair cells and restore ... journal BMC Neuroscience shows that growth hormone ...
... Quest Diagnostics Incorporated (NYSE: DGX ), the ... today issued its annual report on U.S. worker drug ... includes its first state-by-state analysis of methamphetamine positives, based ... the general U.S. workforce from January-December 2010, revealing that ...
Cached Biology News:NSF funds NJIT's participation in program to retain engineering students 2Hawaii, Arkansas and Oklahoma Lead the Nation for Methamphetamine Use in the Workforce, Reveals Quest Diagnostics Drug Testing Index™ 2Hawaii, Arkansas and Oklahoma Lead the Nation for Methamphetamine Use in the Workforce, Reveals Quest Diagnostics Drug Testing Index™ 3Hawaii, Arkansas and Oklahoma Lead the Nation for Methamphetamine Use in the Workforce, Reveals Quest Diagnostics Drug Testing Index™ 4Hawaii, Arkansas and Oklahoma Lead the Nation for Methamphetamine Use in the Workforce, Reveals Quest Diagnostics Drug Testing Index™ 5
Contains 0.2 g/L EDTA4Na in phosphate-buffered saline....
Quantibody Human Angiogenesis Array 1 (1 slide) Class: Quantitative Antibody Arrays Product Group: Antibody Array...
BD IMagnet 1 each...
Hucal Agx Antigen Expression Service Specificity: Hucal Agx ...
Biology Products: